WO2003093827A3 - Diagnostics and drug screening for diseases associated with leucine-rich repeat-containing g-protein coupled receptor 7 (lgr7) - Google Patents

Diagnostics and drug screening for diseases associated with leucine-rich repeat-containing g-protein coupled receptor 7 (lgr7) Download PDF

Info

Publication number
WO2003093827A3
WO2003093827A3 PCT/EP2003/004139 EP0304139W WO03093827A3 WO 2003093827 A3 WO2003093827 A3 WO 2003093827A3 EP 0304139 W EP0304139 W EP 0304139W WO 03093827 A3 WO03093827 A3 WO 03093827A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
lgr7
diagnostics
leucine
diseases associated
Prior art date
Application number
PCT/EP2003/004139
Other languages
French (fr)
Other versions
WO2003093827A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Juergen Franz
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Juergen Franz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts, Juergen Franz filed Critical Bayer Healthcare Ag
Priority to AU2003224112A priority Critical patent/AU2003224112A1/en
Publication of WO2003093827A2 publication Critical patent/WO2003093827A2/en
Publication of WO2003093827A3 publication Critical patent/WO2003093827A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides a human LGR7 which is associated with the hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases, genito-urological diseases, gastro-intestinal diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases, genito-urological diseases, gastro-intestinal diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of LGR7 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2003/004139 2002-05-02 2003-04-22 Diagnostics and drug screening for diseases associated with leucine-rich repeat-containing g-protein coupled receptor 7 (lgr7) WO2003093827A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003224112A AU2003224112A1 (en) 2002-05-02 2003-04-22 Diagnostics and drug screening for diseases associated with leucine-rich repeat-containing g-protein coupled receptor 7 (lgr7)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02009314 2002-05-02
EP02009314.2 2002-05-02

Publications (2)

Publication Number Publication Date
WO2003093827A2 WO2003093827A2 (en) 2003-11-13
WO2003093827A3 true WO2003093827A3 (en) 2004-04-01

Family

ID=29286099

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/004139 WO2003093827A2 (en) 2002-05-02 2003-04-22 Diagnostics and drug screening for diseases associated with leucine-rich repeat-containing g-protein coupled receptor 7 (lgr7)

Country Status (2)

Country Link
AU (1) AU2003224112A1 (en)
WO (1) WO2003093827A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120014870A1 (en) * 2008-12-26 2012-01-19 Forerunner Pharma Research Co., Ltd. Diagnosis and Treatment of Cancer Using Anti-LGR7 Antibody

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999048921A1 (en) * 1998-03-26 1999-09-30 The Board Of Trustees Of The Leland Stanford Junior University Novel mammalian g-protein coupled receptors having extracellular leucine rich repeat regions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999048921A1 (en) * 1998-03-26 1999-09-30 The Board Of Trustees Of The Leland Stanford Junior University Novel mammalian g-protein coupled receptors having extracellular leucine rich repeat regions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BARTSCH O ET AL: "RELAXIN SIGNALLING LINKS TYROSINE PHOSPHORYLATION TO PHOSPHODIESTERASE AND ADENYLYL CYCLASE ACTIVITY", MOLECULAR HUMAN REPRODUCTION, OXFORD, GB, vol. 7, no. 9, September 2001 (2001-09-01), pages 799 - 809, XP008019894, ISSN: 1360-9947 *
HSU SHEAU YU ET AL: "Activation of orphan receptors by the hormone relaxin.", SCIENCE (WASHINGTON D C), vol. 295, no. 5555, 2002, 25 January, 2002, pages 671 - 674, XP002253918, ISSN: 0036-8075 *

Also Published As

Publication number Publication date
WO2003093827A2 (en) 2003-11-13
AU2003224112A8 (en) 2003-11-17
AU2003224112A1 (en) 2003-11-17

Similar Documents

Publication Publication Date Title
WO2003082314A3 (en) Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2003074069A3 (en) Diagnostics and therapeutics for diseases associated with the n-formyl peptide receptor 1 (fpr 1)
WO2004080373A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)
WO2003093816A3 (en) Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
WO2003093827A3 (en) Diagnostics and drug screening for diseases associated with leucine-rich repeat-containing g-protein coupled receptor 7 (lgr7)
WO2004071378A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a)
WO2004038405A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)
WO2003095967A3 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 9(ccr9)
WO2005031345A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor2 (adipor2)
WO2004038421A3 (en) Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41)
WO2004015422A3 (en) Diagnostics and therapeutics for diseases associated with ovarian cancer g-protein coupled receptor 1 (ogr-1)
WO2004015427A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 19 (gpr19)
WO2003100435A3 (en) Diagnostics and therapeutic use of neuromedin u receptor 2 (nmu2)
WO2004071393A3 (en) Diagnostics and therapeutics for diseases associated with glucagon-like peptide 1 receptor (glp1r)
WO2004099783A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor ltb4 (ltb4)
WO2004104577A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
WO2004072651A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine 1f receptor (5-ht1f)
WO2004038408A3 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 14 (gpr14)
WO2003096020A3 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8)
WO2004042405A3 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 3 (gpr3)
WO2004038416A8 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 6 (gpr6)
WO2003076945A3 (en) Diagnostic for diseases associated with g-protein coupled receptor 105 (gpr105)
WO2004038407A3 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)
WO2003100433A3 (en) Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 3 (avpr3)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP